An overview of gene therapy: how vectors deliver therapeutic genes, current applications and areas for improvement.
Gene therapy is a technique for correcting defective genes responsible for disease, defined by GTAC as “the deliberate introduction of genetic material into human somatic cells for therapeutic, prophylactic or diagnostic purposes.”
A carrier molecule, usually a genetically altered virus (retrovirus, adenovirus, adeno-associated virus or HSV type-I), delivers a normal gene to target cells. Approaches include insertion, homologous recombination, selective reverse mutation and altered gene regulation.
Applications include severe combined immune deficiency, chronic granulomatous disorders, haemophilia, sickle cell disease, cancer and neurodegenerative diseases. The first human gene therapy was performed on 14 September 1990. The outlook is promising, but patient selection, side effects, delivery methods and safety still need improvement.
Published in the department’s Annual Report, July 2024 to June 2025. Download the full report
